Streetbeat News

APRE

Aprea Therapeutics, Inc.

Industry

Biotechnology

Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel cancer therapeutics that target DNA damage response pathways. Its lead product candidate is ATRN-119, an oral ATR inhibitor that is in phase 1/2a clinical trial to treat patients with advanced solid tumors. The company's products pipeline also includes ATRN-Backup, an ATR inhibitor; ATRN-W1051 to treat anti-tumor activity; and ATRN-DDRi. Aprea Therapeutics, Inc. is based in Boston, Massachusetts.

Open

3.33

Mkt cap

17M

Volume

17K

High

3.33

P/E Ratio

-1.10

52-wk high

8.85

Low

3.07

Div yield

N/A

52-wk low

2.15

Aprea Therapeutics has announced a new twice daily dosing regimen for its experimental drug ATRN-119 in the ABOYA-119 clinical trial. This change aims to optimize clinical outcomes by enhancing the drug's activity over a 24-hour period.

Portfolio Pulse from

December 11, 2024 | 1:45 pm

Aprea Therapeutics (APRE) has formed a hammer chart pattern, suggesting support and potential trend reversal. Upward earnings estimate revisions further support a positive outlook for the stock.

Portfolio Pulse from

November 13, 2024 | 4:00 pm

Aprea Therapeutics, Inc. (APRE) reported a Q3 loss of $0.64 per share, which was better than the Zacks Consensus Estimate of a $0.75 loss. This is an improvement from the $0.86 loss per share reported a year ago.

Portfolio Pulse from

November 07, 2024 | 3:30 pm

HC Wainwright & Co. has reiterated its Buy rating on Aprea Therapeutics, maintaining a $20 price target. Analyst Joseph Pantginis continues to support the stock, indicating confidence in its potential.